Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rizwana Mohseni

Family Medicine Lake Forest, CA Doctor of Osteopathy

NPI 1013080621 CMS profile 1103944

23672 Birtcher Dr, Unit A, Lake Forest, CA 92630

Open in the dashboard

General payments

$10,580

48 records reported · program years 2019–2025

Research payments

$102,449

Paid to them · 31 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$26,734,480 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Rizwana Mohseni of Lake Forest, CA is reported in the CMS Open Payments database as having received $10,580 across 48 general payments and $102,449 in research payments paid to them. Separately, studies naming them as principal investigator received $26,734,480 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $80 2
2024 General $69 2
2024 Research $50,124 2
2023 General $1,500 9
2023 Research $1,436 5
2022 General $4,118 18
2022 Research $33,732 8
2021 Research $662 9
2020 Research $3,653 6
2019 General $4,813 17
2019 Research $12,842 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rizwana Mohseni
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Rizwana Mohseni were reported at $80. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Rizwana Mohseni Family Medicine median Middle half National median
2019 $4,813 $150 $41–$543 $163
2020 $0 $120 $32–$415 $114
2021 $0 $137 $35–$551 $132
2022 $4,118 $137 $37–$512 $149
2023 $1,500 $149 $42–$545 $160
2024 $69 $156 $44–$560 $164
2025 $80 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca UK Limited $7,638 36 payments
  2. Eli Lilly and Company $2,793 8 payments
  3. Novo Nordisk Inc $101 3 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $48 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $8,478 22 payments
  2. Food and Beverage $2,038 24 payments
  3. Education $65 2 payments
Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $101,564 21 payments
  2. Regeneron Pharmaceuticals, Inc. $885 10 payments

Records

79 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record